Forecasting the progression of Alzheimer's disease using neural networks and a novel preprocessing algorithm

Selkoe D.J., 1999, Basic Neurochemistry: Molecular, Cellular and Medical Aspects 10.1016/j.neurobiolaging.2017.06.027 10.1007/978-1-4612-5174-3_3 10.1016/j.tibtech.2010.09.007 10.1038/nrneurol.2012.263 10.1186/1750-1326-6-85 10.1093/gerona/50A.1.M49 Moore P., 2019, Random forest prediction of Alzheimer's disease using pairwise selection from time series data, PLoS One, 14, e0211558, 10.1371/journal.pone.0211558 10.1002/msj.20279 R.V.Marinescu N.P.Oxtoby A.L.Young E.E.Bron A.W.Toga andM.W.Weiner et al.TADPOLE Challenge: Prediction of Longitudinal Evolution in Alzheimer's Disease.2018 arXiv: 1805.03909 [q‐bio.PE] Singanamalli A., 2017, Cascaded multi‐view canonical correlation (CaMCCo) for early diagnosis of Alzheimer's disease via fusion of clinical, imaging and omic features, Scientific Rep, 7, 8137, 10.1038/s41598-017-03925-0 Gamberger D., 2017, Identification of clusters of rapid and slow decliners among subjects at risk for Alzheimer's disease, Scientific Rep, 7, 6763, 10.1038/s41598-017-06624-y 2016, The need for early detection and treatment in Alzheimer's disease, EBioMedicine, 9, 1, 10.1016/j.ebiom.2016.07.001 Alzheimer's Association.What we know today about Alzheimer's disease.https://www.actionalz.org/research/science/alzheimers_disease_treatments.asp 2010 Accessed September 10 2019 10.1186/alzrt269 I.Mumal.Poor results prompt Takeda and Zinfandel to end phase 3 Alzheimer's therapy trial early.https://alzheimersnewstoday.com/2018/01/31/takeda‐and‐zinfandel‐bring‐early‐end‐to‐phase‐3‐trial‐of‐alzheimers‐therapy‐pioglitazone/ 2018 Accessed September 10 2019 M.Cortez.Merck will end Alzheimer's trial as alternative approach fails.https://www.bloomberg.com/news/articles/2018‐02‐13/merck‐will‐end‐alzheimer‐s‐trial‐as‐alternative‐approach‐fails 2018 Accessed September 10 2019 U.S. Food and Drug Administration.https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM596728.pdf 2018 Accessed September 10 2019 S.Gottlieb.Statement from FDA commissioner Scott Gottlieb M.D. on advancing the development of novel treatments for neurological conditions; part of broader effort on modernizing FDA's new drug review programs.https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm596897.htm 2018 Accessed September 10 2019 10.1016/S1474-4422(15)00093-9 10.1097/WCO.0000000000000460 10.1093/brain/awn146 ADNI Staff.ADNI general procedures manual.https://adni.loni.usc.edu/wp‐content/uploads/2010/09/ADNI_GeneralProceduresManual.pdf 2010 Accessed September 10 2019 10.3233/JAD-170991 10.1109/TMI.2014.2314712 10.1097/00019442-200102000-00013 10.1080/13854046.2015.1119312 Boone K.B., 2005, Comparison of various RAVLT scores in the detection of noncredible memory performance, Arch Clin Neuropsychol, 20, 301, 10.1016/j.acn.2004.08.001 10.1093/geronj/37.3.323 S.Esmaeilzadeh D.I.Belivanis K.M.Pohl andE.Adeli.End‐to‐end Alzheimer's Disease Diagnosis and Biomarker Identification.2018 arXiv: 1810.00523 [cs.CV] 10.1371/journal.pone.0189990 10.1016/j.neuroimage.2011.01.008 10.1023/A:1010920819831 M.M.Ghazi M.Nielsen A.Pai M.J.Cardoso M.Modat andS.Ourselin et al.Robust Training of Recurrent Neural Networks to Handle Missing Data for Disease Progression Modeling.2018 arXiv: 1808.05500 [cs.CV] 10.1109/PRNI.2018.8423955 10.1016/j.neuroimage.2012.10.065